Ovation Science Third Quarter 2024 Earnings: CA$0.005 loss per share (vs CA$0.007 loss in 3Q 2023)
Ovation Science (CSE:OVAT) Third Quarter 2024 Results
Key Financial Results
- Revenue: CA$14.5k (up 230% from 3Q 2023).
- Net loss: CA$178.1k (loss narrowed by 7.8% from 3Q 2023).
- CA$0.005 loss per share (improved from CA$0.007 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ovation Science shares are down 17% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with Ovation Science (at least 5 which are a bit concerning), and understanding these should be part of your investment process.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:OVAT
Ovation Science
Engages in the production, sub-licensing, and sale of cannabis or hemp products in Canada and the United States.
Medium-low and overvalued.
